Helogen, a startup focused on manufacturing biomaterials in space, has announced two significant missions for its HEL-IOS platform, both set to launch in October aboard SpaceX vehicles. These missions will test manufacturing biological materials in orbit, one for a customer and one for Helogen’s own products.
Mission Details:
-
First Mission:
- Objective: Develop polymers for orthopedic applications.
- Recovery: Post-mission, Helogen will attempt to recover the produced biomaterials for further research.
-
Second Mission:
- Partnership: Collaboration with LambdaVision.
- Objective: Demonstrate the creation of proteins for artificial retinas aboard a D-Orbit spacecraft.
Both missions aim to advance Helogen’s capabilities in in-space biological manufacturing, crucial for future regulatory approvals for terrestrial medical applications.
CEO Insights:
Shishir Bankapur, Helogen’s CEO, emphasized the importance of maintaining sterility and accountability during transportation, likening it to ensuring ice cream remains frozen until it reaches the store.
Focus Areas:
- Immediate Goal: Surgical implants, specifically biopolymers for orthopedic surgery.
- Product Advancements: Helogen anticipates creating denser, longer-lasting biomaterials compared to current options.
Business Model:
Helogen’s HEL-IOS platform will serve as a testbed and production site for other customers. The startup has plans to conduct eight missions in the next year, balancing internal developments and customer projects, enhancing revenue potential from both avenues.
Market Expansion:
- Customer Flights: Higher margins due to external partnerships.
- Internal Missions: Expected to generate more material and enable sales of in-space products to medical practices.
Bankapur stated the company’s vision includes not just manufacturing but also playing a key role in the commercialization of innovations derived from space.
